nodes	percent_of_prediction	percent_of_DWPC	metapath
Mebendazole—TUBB4B—Vincristine—muscle cancer	0.53	0.559	CbGbCtD
Mebendazole—CYP1A1—Dacarbazine—muscle cancer	0.181	0.191	CbGbCtD
Mebendazole—ABCB1—Dactinomycin—muscle cancer	0.0613	0.0646	CbGbCtD
Mebendazole—ABCB1—Vincristine—muscle cancer	0.0377	0.0398	CbGbCtD
Mebendazole—ABCB1—Etoposide—muscle cancer	0.0346	0.0365	CbGbCtD
Mebendazole—ABCB1—Doxorubicin—muscle cancer	0.0236	0.0249	CbGbCtD
Mebendazole—ABCB1—Methotrexate—muscle cancer	0.0228	0.0241	CbGbCtD
Mebendazole—CYP3A4—Vincristine—muscle cancer	0.0226	0.0238	CbGbCtD
Mebendazole—CYP3A4—Etoposide—muscle cancer	0.0207	0.0218	CbGbCtD
Mebendazole—CYP3A4—Doxorubicin—muscle cancer	0.0141	0.0149	CbGbCtD
Mebendazole—TUBA1A—embryo—muscle cancer	0.00335	0.085	CbGeAlD
Mebendazole—TUBA1A—smooth muscle tissue—muscle cancer	0.00264	0.0668	CbGeAlD
Mebendazole—TUBA1A—renal system—muscle cancer	0.00254	0.0643	CbGeAlD
Mebendazole—TUBA1A—cardiac atrium—muscle cancer	0.00227	0.0576	CbGeAlD
Mebendazole—TUBB4B—embryo—muscle cancer	0.00223	0.0566	CbGeAlD
Mebendazole—Ketorolac—PTGS2—muscle cancer	0.00201	0.344	CrCbGaD
Mebendazole—TUBA1A—tendon—muscle cancer	0.00198	0.0502	CbGeAlD
Mebendazole—TUBA1A—bone marrow—muscle cancer	0.00192	0.0486	CbGeAlD
Mebendazole—TUBA1A—vagina—muscle cancer	0.00184	0.0466	CbGeAlD
Mebendazole—TUBB4B—smooth muscle tissue—muscle cancer	0.00176	0.0445	CbGeAlD
Mebendazole—Prolonged menses—Vincristine—muscle cancer	0.00172	0.28	CcSEcCtD
Mebendazole—TUBA1A—head—muscle cancer	0.0017	0.043	CbGeAlD
Mebendazole—TUBB4B—renal system—muscle cancer	0.00169	0.0429	CbGeAlD
Mebendazole—Tiaprofenic acid—PTGS2—muscle cancer	0.00164	0.281	CrCbGaD
Mebendazole—TUBA1A—testis—muscle cancer	0.00164	0.0416	CbGeAlD
Mebendazole—Nepafenac—PTGS2—muscle cancer	0.00156	0.267	CrCbGaD
Mebendazole—TUBB4B—cardiac atrium—muscle cancer	0.00151	0.0384	CbGeAlD
Mebendazole—TUBB4B—tendon—muscle cancer	0.00132	0.0335	CbGeAlD
Mebendazole—TUBB4B—bone marrow—muscle cancer	0.00128	0.0324	CbGeAlD
Mebendazole—TUBB4B—vagina—muscle cancer	0.00122	0.0311	CbGeAlD
Mebendazole—TUBB4B—head—muscle cancer	0.00113	0.0287	CbGeAlD
Mebendazole—TUBB4B—testis—muscle cancer	0.00109	0.0277	CbGeAlD
Mebendazole—CYP1A1—renal system—muscle cancer	0.000947	0.024	CbGeAlD
Mebendazole—CYP1A1—cardiac atrium—muscle cancer	0.000848	0.0215	CbGeAlD
Mebendazole—CYP3A4—renal system—muscle cancer	0.000695	0.0176	CbGeAlD
Mebendazole—CYP1A1—vagina—muscle cancer	0.000686	0.0174	CbGeAlD
Mebendazole—ABCB1—embryo—muscle cancer	0.00065	0.0165	CbGeAlD
Mebendazole—CYP1A1—head—muscle cancer	0.000633	0.0161	CbGeAlD
Mebendazole—Ketoprofen—PTGS2—muscle cancer	0.000632	0.108	CrCbGaD
Mebendazole—ABCB1—renal system—muscle cancer	0.000492	0.0125	CbGeAlD
Mebendazole—Menorrhagia—Vincristine—muscle cancer	0.000486	0.0792	CcSEcCtD
Mebendazole—ABCB1—bone marrow—muscle cancer	0.000372	0.00943	CbGeAlD
Mebendazole—ABCB1—vagina—muscle cancer	0.000356	0.00903	CbGeAlD
Mebendazole—ABCB1—head—muscle cancer	0.000329	0.00834	CbGeAlD
Mebendazole—ABCB1—testis—muscle cancer	0.000318	0.00806	CbGeAlD
Mebendazole—Neutropenia—Dactinomycin—muscle cancer	0.000236	0.0385	CcSEcCtD
Mebendazole—Neutropenia—Vincristine—muscle cancer	0.000211	0.0344	CcSEcCtD
Mebendazole—Agranulocytosis—Dactinomycin—muscle cancer	0.00021	0.0342	CcSEcCtD
Mebendazole—Hepatitis—Dactinomycin—muscle cancer	0.000202	0.0329	CcSEcCtD
Mebendazole—Neutropenia—Etoposide—muscle cancer	0.000171	0.0278	CcSEcCtD
Mebendazole—Agranulocytosis—Etoposide—muscle cancer	0.000152	0.0248	CcSEcCtD
Mebendazole—Convulsion—Vincristine—muscle cancer	0.000136	0.0222	CcSEcCtD
Mebendazole—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000118	0.0191	CcSEcCtD
Mebendazole—Abdominal pain—Dactinomycin—muscle cancer	0.000114	0.0185	CcSEcCtD
Mebendazole—Convulsion—Etoposide—muscle cancer	0.00011	0.018	CcSEcCtD
Mebendazole—Hypersensitivity—Dactinomycin—muscle cancer	0.000106	0.0172	CcSEcCtD
Mebendazole—Gastrointestinal pain—Vincristine—muscle cancer	0.000105	0.0171	CcSEcCtD
Mebendazole—Neutropenia—Methotrexate—muscle cancer	0.000102	0.0167	CcSEcCtD
Mebendazole—Abdominal pain—Vincristine—muscle cancer	0.000101	0.0165	CcSEcCtD
Mebendazole—Hypersensitivity—Vincristine—muscle cancer	9.46e-05	0.0154	CcSEcCtD
Mebendazole—Agranulocytosis—Methotrexate—muscle cancer	9.12e-05	0.0148	CcSEcCtD
Mebendazole—Rash—Dactinomycin—muscle cancer	9.06e-05	0.0148	CcSEcCtD
Mebendazole—Neutropenia—Doxorubicin—muscle cancer	8.87e-05	0.0144	CcSEcCtD
Mebendazole—Hepatitis—Methotrexate—muscle cancer	8.77e-05	0.0143	CcSEcCtD
Mebendazole—Gastrointestinal pain—Etoposide—muscle cancer	8.51e-05	0.0138	CcSEcCtD
Mebendazole—Urticaria—Etoposide—muscle cancer	8.26e-05	0.0135	CcSEcCtD
Mebendazole—Abdominal pain—Etoposide—muscle cancer	8.22e-05	0.0134	CcSEcCtD
Mebendazole—Rash—Vincristine—muscle cancer	8.1e-05	0.0132	CcSEcCtD
Mebendazole—Dermatitis—Vincristine—muscle cancer	8.09e-05	0.0132	CcSEcCtD
Mebendazole—Agranulocytosis—Doxorubicin—muscle cancer	7.89e-05	0.0129	CcSEcCtD
Mebendazole—Hypersensitivity—Etoposide—muscle cancer	7.66e-05	0.0125	CcSEcCtD
Mebendazole—Hepatitis—Doxorubicin—muscle cancer	7.59e-05	0.0124	CcSEcCtD
Mebendazole—Convulsion—Methotrexate—muscle cancer	6.61e-05	0.0108	CcSEcCtD
Mebendazole—Rash—Etoposide—muscle cancer	6.56e-05	0.0107	CcSEcCtD
Mebendazole—Dermatitis—Etoposide—muscle cancer	6.55e-05	0.0107	CcSEcCtD
Mebendazole—Convulsion—Doxorubicin—muscle cancer	5.73e-05	0.00933	CcSEcCtD
Mebendazole—Gastrointestinal pain—Methotrexate—muscle cancer	5.09e-05	0.0083	CcSEcCtD
Mebendazole—Urticaria—Methotrexate—muscle cancer	4.95e-05	0.00806	CcSEcCtD
Mebendazole—Abdominal pain—Methotrexate—muscle cancer	4.92e-05	0.00802	CcSEcCtD
Mebendazole—Hypersensitivity—Methotrexate—muscle cancer	4.59e-05	0.00747	CcSEcCtD
Mebendazole—Gastrointestinal pain—Doxorubicin—muscle cancer	4.41e-05	0.00718	CcSEcCtD
Mebendazole—Urticaria—Doxorubicin—muscle cancer	4.29e-05	0.00698	CcSEcCtD
Mebendazole—Abdominal pain—Doxorubicin—muscle cancer	4.26e-05	0.00694	CcSEcCtD
Mebendazole—Hypersensitivity—Doxorubicin—muscle cancer	3.97e-05	0.00647	CcSEcCtD
Mebendazole—Rash—Methotrexate—muscle cancer	3.93e-05	0.0064	CcSEcCtD
Mebendazole—Dermatitis—Methotrexate—muscle cancer	3.92e-05	0.00639	CcSEcCtD
Mebendazole—Rash—Doxorubicin—muscle cancer	3.4e-05	0.00554	CcSEcCtD
Mebendazole—Dermatitis—Doxorubicin—muscle cancer	3.4e-05	0.00553	CcSEcCtD
